AstraZeneca's (AZN -1.6% in London) fostamatinib pill was inferior to Abbott Labs' (ABT) Humira...

|About: AstraZeneca Group plc (AZN)|By:, SA News Editor

AstraZeneca's (AZN -1.6% in London) fostamatinib pill was inferior to Abbott Labs' (ABT) Humira in controlling rheumatoid arthritis symptoms in a Phase II trial. AstraZeneca can still pin its hopes, though, on a Phase III study in which fostamatinib is being given with other drugs. Results are due out in H1 next year. (PR)